



Date : July 08, 2019

Dr. Salha Mohd.Bu Jassoum  
Senior Consultant, Oncology

Hamad Medical Corporation

This letter is in reference to the clinical trial entitled "A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2POSITIVE EARLY BREAST CANCER" Submitted by HMC on 24 April 2019 and file completed on 04 July 2019.

Research proposal	Document initially reviewed
Protocol number MRC-01-19-044	<ol style="list-style-type: none"><li>1) MRC-01-19-044_AR_Booklet Label_Countrypage_11Pages</li><li>2) MRC-01-19-044_Arabic Patient Card 1_V1 FINAL_31Oct2018_CF_02Pages</li><li>3) MRC-01-19-044_ClinicalStudy_CaseReportForm_98Pages</li><li>4) MRC-01-19-044_English_Patient Card 1 Version 1 0_Final_31Oct2018-CF_02Pages</li><li>5) MRC-01-19-044_HMC-IRBApporval_26Mar19</li><li>6) MRC-01-19-044_Investigator Brochure_PH FDC SC_49Pages</li><li>7) MRC-01-19-044_Investigator Brochure_Herceptin_202Pages</li><li>8) MRC-01-19-044_Investigator Brochure_Perteja_236Pages</li><li>9) MRC-01-19-044_Qatar PPA Form, Version 1 0, dated 07Dec2018_Ara_04Pages</li><li>10) MRC-01-19-044_Qatar, PPA Form, Version 1 0, dated 07Dec2018_05Pages</li><li>11) MRC-01-19-044_-Qatar-TVC-Patient Card-31Oct2018_03Pages</li><li>12) MRC-01-19-044_TOO_SRD-0110717_template_v3_0-FINAL_IQVIA_03Pages</li><li>13) MRC-01-19-044_EORTC QLQ-C30_Ara_04Pages</li><li>14) MRC-01-19-044_EORTC QLQ-C30_Eng_03Pages</li><li>15) MRC-01-19-044_HealthcareProfessionalSurvey_PharmacyDrugPreparationArea_Ara_07Pages</li><li>16) MRC-01-19-044_HealthcareProfessionalSurvey_PharmacyDrugPreparationArea_Eng_07Pages</li><li>17) MRC-01-19-044_HealthcareProfessionalSurvey_TreatmentRoom_Ara_08Pages</li><li>18) MRC-01-19-044_HealthcareProfessionalSurvey_TreatmentRoom_Eng_09Pages</li><li>19) MRC-01-19-044_PatientPreferenceQuestionnaire_Ara_02Pages</li><li>20) MRC-01-19-044_PatientPreferenceQuestionnaire_Eng_02Pages</li></ol>



- 21) MRC-01-19-044\_ResearchConsentForm\_Ara\_15Pages
- 22) MRC-01-19-044\_ResearchConsentForm\_Eng\_15Pages
- 23) MRC-01-19-044\_ResearchProtocol\_V2\_117Pages
- 24) MRC-01-19-044\_SCmanual\_Eng\_79Pages
- 25) MRC-01-19-044\_TASQ\_IV\_Ara\_03Pages
- 26) MRC-01-19-044\_TASQ\_IV\_Eng\_03Pages
- 27) MRC-01-19-044\_TASQ\_SC\_Ara\_03Pages
- 28) MRC-01-19-044\_TASQ\_SC\_Eng\_03Pages

**Other documents:**

- 29) MRC-01-19-044\_-List of Participating Countries-10Dec2018
- 30) MRC-01-19-044\_ - Spain - Initial Submission Approval
- 31) MRC-01-19-044\_BMC IRB approval
- 32) MRC-01-19-044\_HAMMOUD HOSPITAL APPROVAL-initial approval

Upon review of the submitted documents, the Ministry of Public Health (MoPH) support the conduct of this clinical trial under the condition of the strict adherence to the bellow condition. Please be noted that it is the institution, sponsor and the principal investigator's responsibility, to ensure that this clinical trial is conducted in compliance with MoPH regulations and the principle of International Conference on Harmonization( ICH)- Good Clinical Practice(GCP), and to ensure the below responsibilities are fulfilled:

**The PI's responsibilities**

- 1- The safety and well being of the participants are protected
- 2- Research involving human participants begins only after IRB review and approval
- 3- The research is conducted in accordance with the local IRB-approved protocol, including the approved recruitment and consent procedures
- 4- When informed consent is required, it is obtained and documented before research participation begins
- 5- All unanticipated problems, including adverse event(s) are reported in accordance with IRB's policy on reporting unanticipated problems including adverse events
- 6- All investigators and study staff listed on the project are informed of changes and unanticipated problems, including adverse events, involving risks to subjects or others
- 7- The continuing review submission to the IRB should be submitted with a sufficient time to allow for IRB review and approval and provide an opportunity for response by the principal investigator to any stipulation of the local registered IRB
- 8- When the research protocol ends, a final report is submitted to the IRB
- 9- Adequate and accurate research records are kept and retained
- 10- The confidentiality of data is maintained at all times



- 11- Upon request for audit, monitoring and oversight of the research, research records are made available to MoPH
- 12- When supervising the conduct of the research , The PI ensures that study personnel :
  - Are qualified by training and experience , and credential if necessary to perform study-related tasks that have been assigned to them,
  - Are aware of regulatory and policy requirement and standards for conduct of human subjects research
  - Have a complete understanding of the details of the protocol relevant to the tasks they will be performing
  - Follow the IRB-approved protocol
  - Are informed of any pertinent changes to the protocol during the conduct of the study and are educated or given additional training, as appropriate.

**It is the Sponsor and HMC responsibility to:**

1. Monitor the safety and wellbeing of research participants
2. Ensure that informed consents are in place
3. Provide enough support to the PI to fulfill his above mentioned responsibilities
4. Protect the privacy and confidentiality of participant
5. Provide the appropriate training to the involved research staff
6. Amendment to the protocol are well documented.
7. Substantial protocol's amendment must be reported to the MoPH. A substantial amendment is defined as an amendment to the terms of the protocol or any other supporting documentation that is likely to affect to a significant degree: (a) the safety of the subjects of the trial, (b) the scientific value of the trial, (c) the conduct or management of the trial.
8. Conduct continuous monitoring during the conduct of the trial
9. Conduct periodic reviews through the trial duration
10. Report all serious adverse events to the MoPH
11. Keep IRB meeting minutes and trial related documents.
12. The MoPH requires that any serious adverse events involving the device under investigation, from all investigational center are reported to the MoPH.
13. The serious adverse event should be notified in accordance with the MOPH regulation: *"Guidelines on Reviewing and Reporting Unanticipated Problems Involving Risks to Subject or Others and Adverse Events"*

**It is the Independent Data and Safety Monitoring Board responsibility (when applicable) to:**


- 1- Review the trial prior to its implementation
- 2- Periodically and regularly review and evaluate the accumulated study data for participant safety, study conduct and progress, and when appropriate, efficacy
- 3- Make recommendations concerning the continuation, modification, or termination of the trial
- 4- Ensure that the timeliness, completeness and accuracy of the data submitted to them to review are sufficient for evaluation of the safety and welfare of study participants
- 5- Share Report resulting from this meeting with HMC-IRB, the sponsor and MOPH



Please note that the MoPH should be notified at the end of the trial, or otherwise if the trial is suspended.

For any enquiries, please contact the Research Division at MoPH via: [irb@moph.gov.qa](mailto:irb@moph.gov.qa)

Sincerely yours,

Neyla Dahane  
  
on behalf of

Dr. Eman Sadoun

Manager, Health Research Governance Department

Ministry of Public Health

974-4407-036

[dresadoun@MOPH.GOV.QA](mailto:dresadoun@MOPH.GOV.QA)